N30 Pharma Raises $30M

Boulder-based N30 Pharma, a firm developing treatments for respiratory, cardiovascular, and inflammatory diseases, announced today that it has raised $10M in a new financing round. According to the firm, it is adding Dr. Howard Furst of Deerfield Management to its board of directors along with the new funding. N30 Pahrma's drugs are being applied to such diseases as cystic fibrosis. The firm said the funding will help move its first drug, N6022, into human testing, as well as go towards development of other new drugs. More information »